Natera Gains Medicare Coverage for WGS Signatera, Leerink Reaffirms Price Target

Natera Inc. (NASDAQ:NTRA) is one of billionaire Stan Druckenmiller’s top stock picks with huge upside potential. Leerink Partners analysts reiterated their Outperform rating on Natera Inc. (NASDAQ:NTRA) on June 4. Given recent adjustments to Medicare’s reimbursement of Natera’s WGS Signatera assay, the analysts maintained their price target for the company at $220.

Natera Gains Medicare Coverage for WGS Signatera, Leerink Reaffirms Price Target

Natera Inc. (NASDAQ:NTRA) recently revealed that MolDX had approved Medicare coverage for its WGS Signatera assay. The update followed the findings of a bridging study that showed similar performance between the WGS Signatera and the previously released WES Signatera. The WGS Signatera assay has been expanded to encompass a number of ailments, including colorectal cancer, breast cancer, bladder cancer, and pan-cancer immunotherapy monitoring.

Analysts expect that WES Signatera will continue to dominate Signatera volumes in the near term, despite the recent coverage. That said, now that it is eligible for reimbursement, the WGS Signatera assay may see a modest rise in usage.

One of the top providers of cell-free DNA and genetic testing, Natera Inc. (NASDAQ:NTRA) focuses primarily on women’s health, cancer, and organ health.

While we acknowledge the potential of NTRA as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

Read More: 10 Best Magic Formula Stocks for 2025 and 10 Best Retirement Stocks to Buy According to Hedge Funds

Disclosure: None.